Neuphoria Therapeutics Q1 2026 Results: Net Loss of $1.43M, Loss Narrows
Neuphoria Therapeutics Inc., formerly Bionomics Limited, completed its re-domiciliation from Australia to Delaware in December 2024. As of November 13, 2026, the company reported 5,411,334 shares of common stock outstanding and is currently pursuing a proposed merger with Scancell Holdings plc.
- Key figure
- Net loss $1.43M